BEACOPP regimen
E499491
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
All labels observed (3)
| Label | Occurrences |
|---|---|
| BEACOPP regimen canonical | 1 |
| Bleomycin Etoposide Adriamycin Cyclophosphamide Oncovin Procarbazine Prednisone regimen | 1 |
| escalated BEACOPP | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5160993 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: BEACOPP regimen Context triple: [Hodgkin lymphoma, treatedWith, BEACOPP regimen]
-
A.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
B.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
C.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
D.
REGN-EB3
REGN-EB3 is a monoclonal antibody cocktail developed by Regeneron to treat Ebola virus disease, shown to significantly reduce mortality in clinical trials.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: BEACOPP regimen Target entity description: The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
A.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
B.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
C.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
D.
REGN-EB3
REGN-EB3 is a monoclonal antibody cocktail developed by Regeneron to treat Ebola virus disease, shown to significantly reduce mortality in clinical trials.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
Hodgkin lymphoma treatment
ⓘ
chemotherapy regimen ⓘ combination chemotherapy protocol ⓘ |
| alsoKnownAs |
BEACOPP
ⓘ
escalated BEACOPP ⓘ
linked to:
BEACOPP regimen
standard BEACOPP ⓘ |
| comparedWith | ABVD regimen ⓘ |
| componentDrug |
bleomycin
ⓘ
cyclophosphamide ⓘ doxorubicin ⓘ etoposide ⓘ prednisone ⓘ procarbazine ⓘ vincristine ⓘ |
| contraindicationContext | often avoided in very elderly or frail patients due to toxicity ⓘ |
| cycleLength | 21 days ⓘ |
| developedFor | improving progression-free survival in advanced Hodgkin lymphoma ⓘ |
| drugClassOfComponent |
alkylating agents
ⓘ
anthracyclines ⓘ corticosteroids ⓘ topoisomerase II inhibitors ⓘ vinca alkaloids ⓘ |
| fullName |
Bleomycin Etoposide Adriamycin Cyclophosphamide Oncovin Procarbazine Prednisone regimen
ⓘ
linked to:
BEACOPP regimen
|
| guidelineContext | considered in high-risk Hodgkin lymphoma in European guidelines ⓘ |
| hasVariant |
baseline BEACOPP
ⓘ
escalated-dose BEACOPP ⓘ |
| indication |
advanced-stage Hodgkin lymphoma
ⓘ
high-risk Hodgkin lymphoma ⓘ unfavorable Hodgkin lymphoma ⓘ |
| namedAfter | initials of its component drugs ⓘ |
| requiresMonitoring |
blood counts
ⓘ
organ function ⓘ |
| routeOfAdministration |
intravenous
ⓘ
oral ⓘ |
| supportiveCareRequirement |
antiemetic prophylaxis
ⓘ
growth factor support in many protocols ⓘ |
| toxicity |
infection risk
ⓘ
infertility risk ⓘ myelosuppression ⓘ pulmonary toxicity ⓘ secondary malignancies risk ⓘ |
| treatmentGoal |
increase cure rate
ⓘ
reduce relapse risk ⓘ |
| treatmentSetting |
curative intent therapy
ⓘ
first-line therapy for advanced Hodgkin lymphoma ⓘ |
| typicalNumberOfCycles |
6
ⓘ
8 ⓘ |
| usedIn | combination with radiotherapy in some protocols ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: BEACOPP regimen Description of subject: The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
BEACOPP regimen
→
fullName
→
Bleomycin Etoposide Adriamycin Cyclophosphamide Oncovin Procarbazine Prednisone regimen
ⓘ
linked to: BEACOPP regimen
linked to: BEACOPP regimen